The Harmonized Interventions to Maintain Health Via Appropriate Risk Factor Modification and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Pilot Study

Cancer Clinical Trial

— HIMALAYAS-P  

Official title:

The Harmonized Interventions to Maintain Health Via Appropriate Risk Factor Modification and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Pilot Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04598646
• Other study ID #: 21-5391.0
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 1, 2022
• Est. completion date: December 2027

Study information

• Verified date: February 2024
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cardiovascular disease (CVD) is a major contributor to morbidity and mortality in pediatric, adolescent and young adult (AYA) cancer survivors (hereafter referred to as PAYA-CS). Exercise is a cornerstone of CVD prevention and treatment; yet, exercise has not been adopted as a standard of care in PAYA-CS at high CVD risk. The HIMALAYAS trial is designed to evaluate the feasibility and preliminary impact of an exercise-based CR on cardiovascular (CV) and psychosocial health, as well as CVD risk, in PAYA-CS with mild heart dysfunction (stage B heart failure (SBHF)). The primary objective of the HIMALAYAS pilot study is to assess the feasibility of a two-phase randomized controlled trial designed to evaluate impact of a 'CR-like' cardio-oncology rehabilitation (CORE) intervention on CV, psychosocial, and behavioural outcomes at 6 and 24 months, compared to behavioural support only (Support) in PAYA-CS. Screened PAYA-CS without SBHF and those with SBHF who do not participate in the RCT will be enrolled in a passive behavioural support (Support) group. The primary outcome is study feasibility, defined according to three primary criteria (i.e., participant recruitment, safety, and adherence). Secondary outcomes include additional feasibility metrics (e.g., intervention safety and tolerability) and exploratory efficacy outcomes including peak cardiorespiratory fitness (VO2peak), cardiac function (e.g., global longitudinal strain (GLS)), CVD risk factor control (e.g. insulin resistance), and patient-reported outcomes (e.g. anxiety). Our central hypothesis is that the conduct of a larger RCT comparing the impact of CORE versus non-intervention control will be feasible indicated by the achievement of our primary feasibility criteria. Our exploratory hypothesis is that we will generate preliminary evidence that CORE can improve VO2peak, cardiac function, CVD risk factor, and patient-reported outcomes over 6- and 24-month timepoints, relative to control.

Description:

Over 90,000 North Americans are diagnosed with cancer before the age of 40. Improved cancer therapies have led to an exponential growth in the number of pediatric, adolescent, and young adult cancer survivors (PAYA-CS) who are expected to live 50-60 years beyond diagnosis. However, PAYA-CS are at increased risk of developing multiple cancer- and treatment-related morbidities including poor fitness (e.g., low VO2peak), hypertension (HTN), diabetes, and poor mental health, which all contribute to premature cardiovascular disease (CVD). The prevalence of CVD events (e.g. heart failure, heart attack, stroke) is up to 23.8% in adult survivors of pediatric cancers with long term follow-up after treatment. The incidence of subclinical CVD, which is a precursor to CVD events, is even higher in PAYA-CS; up to 40%, 11%, and 5% experience subclinical cardiomyopathy measured by abnormal global longitudinal strain (GLS), diastolic dysfunction (DD) or mild reduction in left ventricular ejection fraction (LVEF), respectively, and 18% experience reduced aerobic fitness. The treatment of modifiable CVD risk factors must be considered a fundamental target for improving CVD health-related outcomes in PAYA-CS. To this end, exercise and best-practices for CVD risk factor modification are integral to a cardiac rehabilitation (CR) model. Traditional cardiac rehabilitation models for patients with CVD (consisting of exercise, CVD risk factor treatment, and patient education) are safe and effective in improving HRQoL, morbidity, and mortality risk. However, by virtue of their age and low short-term CVD risk, PAYA-CS do not meet traditional criteria for initiating CR and are less likely to receive treatments to reduce CVD risk.

PAYA-CS with stage B heart failure (SB¬HF): (1) are at high risk for subsequent HF/CVD death; (2) have lower cardiopulmonary fitness; and (3) are more likely to benefit from CVD risk factor management. Considering that PAYA-CS have an estimated 33% prevalence of SBHF, this vulnerable cohort of cancer survivors represent an opportunity for intervention that is highly feasible and potentially impactful. Exercise is a preferred method for optimizing health and survival in PAYA-CS. However, we need models that safely and effectively deliver exercise interventions that meet the unique needs of this population. The cardio-oncology rehabilitation (CORE) model is an intervention that would provide PAYA-CS with SBHF a supervised and home-based exercise therapy, CVD risk factor modification, and behavioural support to reduce the risk of CVD. Nevertheless, due to the ambitious nature of the study, it is vital that we conduct a pilot version of the study to determine the feasibility and needed changes to achieve the best possible results.

The primary objective of the HIMALAYAS pilot study is to assess the feasibility, safety, and tolerability of a (1) two-arm RCT-based comparison of the CORE and Support interventions in PAYA-CS with SBHF, and (2) parallel passive behavioural support (PBS) cohort of PAYA-CS at high-risk of cancer-related CVD. The exploratory objectives of the study include (1) to compare the changes in primary exploratory outcome (VO2peak) and secondary exploratory outcomes (markers of cardiac function, CVD risk factor management, and patient-reported outcomes) between a CORE and Support intervention for PAYA-CS from baseline (T0) to 6-month (T1) follow-up and (2) to compare the changes in the primary and secondary exploratory outcomes between (1) CORE and Support from T0 to 12-month (T2) and 24-month (T3) follow-up, and (2) CORE, Support, and PBS from T0 to T3.

Cardio-oncology Rehabilitation (CORE) Group: CORE consists of exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period.

Support Group: The Support group will receive the behavioural support only. The timing and nature of all education, information, and peer support provided to Support participants will be identical to what is provided to CORE participants. The key difference in the long-term behavioural support strategy between CORE and Support participants is how weekly exercise goals are defined. Unlike the CORE participants who will be encouraged to use the personal activity intelligence (PAI) Score, Support participants will be given the challenge of meeting and maintaining the updated physical activity (PA) guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous-intensity PA per week).

Passive Behavioural Support (PBS) Groups: All PBS cohort participants will receive the same wrist-worn heart rate monitor and PA tracker as the CORE and Support participants. However, PBS participants will be blindly randomized to one of two passive behavioural support interventions (PBS1 and PBS2). PBS1 participants will be asked to download the same PAI Health application as CORE participants and will similarly be given the challenge of meeting and maintaining a weekly PAI Score ≥100 throughout the 18-month follow-up period. PBS2 participants will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: December 2027
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Be a PAYA-CS, defined as =39 years of age at the time of cancer diagnosis;

• Be 18-45 years of age at the time of enrolment;

• Received cancer treatment(s) with known cardiovascular risks (e.g. anthracyclines, radiotherapy, trastuzumab, platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors);

• Be cancer-free at the time of enrollment.

• Diagnosed with SBHF prior to or at baseline (LVEF<53/54%, GLS >-18%, or diastolic dysfunction).

Exclusion Criteria:

• An absolute or relative contraindication to exercise according to the American College of Sports Medicine (ACSM) guidelines;

• Untreated physical or mental health concerns that preclude safe and effective exercise participation;

• Established CVD (excluding mildly reduced LVEF as described above);

• Be currently engaging in high-intensity exercise (>1 high-intensity exercise session per week);

• Substantial barriers to completing study protocol (e.g. living too far away and being unable to attend testing and exercise training sessions) or unwillingness to comply with the study protocol (e.g. individual intends to start performing regular HIIT exercise regardless of randomization).

Related Conditions & MeSH terms

• Cancer
• Cardiotoxicity
• Heart Failure

Intervention

Behavioral:
• Cardio-oncology Rehabilitation (CORE)
Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
• Support
Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.

Locations

Country	Name	City	State
Canada	University Health Network	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	VO2peak	VO2peak measured by CPET	baseline, 6-, 12- and 24-month follow ups
Other	Cardiac function	2D LVEF measured by echocardiogram	baseline, 6-, 12- and 24-month follow ups
Other	Cardiac function	3D LVEF measured by echocardiogram	baseline, 6-, 12- and 24-month follow ups
Other	Cardiac function	GLS measured by echocardiogram	baseline, 6-, 12- and 24-month follow ups
Other	Resting blood pressure	Measured with an average of 3 readings (after discarding an initial test reading) by an automated measurement device as per the Hypertension Canada guidelines.	baseline, 6-, 12- and 24-month follow ups
Other	Resting heart rate	Measured with an average of 2 readings taken via ECG during the resting period during the cardiac screening procedures.	baseline, 6-, 12- and 24-month follow ups
Other	Hyperlipidemia	Measured through fasting cholesterol profile and Apo B levels	baseline, 6-, 12- and 24-month follow ups
Other	Diabetes and diabetes risk	Measured through fasting glucose	baseline, 6-, 12- and 24-month follow ups
Other	Diabetes and diabetes risk	Measured through whole-body insulin sensitivity (Matsuda index)	baseline, 6-, 12- and 24-month follow ups
Other	Diabetes and diabetes risk	Measured through hepatic insulin sensitivity (HOMA-IR)	baseline, 6-, 12- and 24-month follow ups
Other	Diabetes and diabetes risk	Measured through pancreatic beta-cell function (ISSI-2).	baseline, 6-, 12- and 24-month follow ups
Other	Diabetes and diabetes risk	Measured through fasting insulin	baseline, 6-, 12- and 24-month follow ups
Other	Physical activity	Measured through Godin Leisure Time PA Questionnaire (GLTPAQ). Score of >24 = active, score of 14-23 = moderately active, score of <14 = insufficiently active	baseline, 6-, 12- and 24-month follow ups
Other	Physical activity	Measured through wrist-worn heart rate with physical activity monitor	baseline, 6-, 12- and 24-month follow ups
Other	Social support	Measured using the Social Support Survey-Clinical (SSS-C) form, a 5-item survey designed to measure five dimensions of social support (listening, task challenge, emotional reality confirmation, and tangible assistance); higher score = more social support	baseline, 6-, 12- and 24-month follow ups
Other	Exercise self-efficacy	Measured using the Multidimensional Self-Efficacy for Exercise Scale (MSES) to measure three behavioural subdomains: task, scheduling, and coping; Scale 0-90, higher score indicates higher self-efficacy for exercise.	baseline, 6-, 12- and 24-month follow ups
Other	Dietary habits	Measured using the National Health and Nutrition Examination Survey (NHANES) Food Frequency Questionnaire (FFQ), a 139-item, semi-quantitative inventory to assess the potential influence of dietary changes on primary and secondary outcomes.	baseline, 6-, 12- and 24-month follow ups
Other	Smoking status	Measured using self-reported measures to determine the potential influence of changes in smoking habits on primary and secondary outcomes.	baseline, 6-, 12- and 24-month follow ups
Other	Anxiety	Measured using the Generalized Anxiety Disorder (GAD-7), a 7-item inventory that assesses 2-week anxiety symptom frequency on a 0-3 scale, with higher scores reflecting higher symptom frequency. A cut-off of =10 indicates some degree of clinical anxiety	baseline, 6-, 12- and 24-month follow ups
Other	Depression	Measured using the Patient Health Questionnaire (PHQ-9), a 9-item inventory that assesses 2-week depressive symptom frequency on a 0-3 scale, with higher scores reflecting higher symptom frequency. The PHQ-9 has been validated in cancer survivors using a cut-off of =8 to indicate some degree of clinical depression.	baseline, 6-, 12- and 24-month follow ups
Other	Health-related quality of life	Measured using the Medical Outcomes Survey Short-Form, (SF-12).	baseline, 6-, 12- and 24-month follow ups
Other	Therapeutic alliance	Measured using the Working Alliance Inventory Short-Revised (WAI-SR) form. Increased score indicates therapeutic alliance.	baseline, 6-, 12- and 24-month follow ups
Primary	Patient Access and Recruitment (feasibility target: >50% of eligible participants)	Defined as the percent of consenting patients based on the total number of otherwise eligible participants (OEP; patients meeting all eligibility criteria) approached	Throughout study recruitment, up to 2 years
Primary	Testing- and intervention-related serious adverse events (feasibility target: none)	Defined as the number and frequency of testing- and intervention-related serious adverse events (SAEs) according to the Common Terminology Criteria for Adverse Events	Initiation through end of study recruitment 12 months
Primary	Patient exercise adherence (feasibility target: >=70% of prescribed)	Defined as relative dose intensity as the percent of total dose of exercise performed relative to the total planned dose prescribed and quantified according to metabolic equivalents	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Patient identification rate (feasibility target: >=50% of OEP)	Defined as the average number of OEP identified each month	Initiation through end of study recruitment 12 months
Secondary	Baseline assessment rate (feasibility target >=90% of consenting participants)	Defined as the percent of consenting patients who successfully complete baseline assessments based on the total number of consenting patients	Initiation through end of study recruitment 12 months
Secondary	Testing- and intervention-related non-serious adverse events (feasibility target <=20% of consenting participants)	Defined as the number and frequency of testing- and intervention-related non-serious adverse events	Initiation through end of study recruitment 12 months
Secondary	Testing performance (feasibility target >=95% of consenting participants)	Defined as the percent completion of all cardiopulmonary exercise tests (CPETs) tests at baseline (T0) and primary follow-up (T1)	Initiation through end of study recruitment 12 months
Secondary	Testing modality adaptation (descriptive)	Defined as the percent of all tests which are adapted for functional or safety reasons	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Training modality adaptation (descriptive)	Defined as the percent of all exercise sessions which are adapted for functional or safety reasons	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Permanent treatment discontinuation (feasibility target <=15% of participants)	Defined as the percent of patients who discontinue intervention participation prior to the planned end of the intervention period	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Treatment interruption (feasibility target <=15% of participants)	Defined as the percent of patients who miss =>3 consecutive sessions within the intervention period	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Dose modification (feasibility target <=25% of participants)	Defined as the percent of exercise sessions requiring a dose reduction during training (i.e., intensity or duration) relative to the total number of sessions completed. Total number of exercise sessions with a reduction in intensity or a reduction in duration will be combined into the numerator when calculating the percentage of affected sessions.	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Early session termination (feasibility target <=25% of participants)	Defined as the percent of exercise sessions requiring unplanned early termination	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Pretreatment intensity modification (feasibility target <=25% of participants)	Defined as the percent of sessions which required pre-exercise modification of the target exercise intensity due to a pre-exercise screening indication (e.g., fatigue, pain)	Initiation throughout end of CORE intervention, an average of 6 months
Secondary	Exercise compliance (feasibility target >=70% of prescribed)	Defined as the percent of exercise sessions completed based on the total number of sessions prescribed.	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Medication compliance (feasibility target >=70% of prescribed)	Defined as the percent of pharmaceutical doses taken based on the total number of doses prescribed (applicable only to those that are provided pharmaceutical therapy for CVD risk factor modification.	Initiation throughout end of CORE intervention at a maximum of 6 months post-randomization
Secondary	Behavioural compliance (feasibility target >=70% of prescribed)	Defined as the percent of behavioural support resources accessed, based on the number of doses prescribed	Initiation throughout end of study, an average of 2 years
Secondary	Physical activity compliance (feasibility target >=70% of prescribed)	defined as the average number of participants achieving their weekly PA goals of meeting and maintaining either a PAI-Score of =100 or weekly cancer exercise guidelines (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).	Initiation throughout end of study, an average of 2 years
Secondary	Attrition (feasibility target <=15% loss to follow-up)	Defined as the percent loss to follow-up (not completing follow-up assessments)	Initiation throughout end of 6 months post-intervention period